Penicillin G Per Se Or Salt Thereof (e.g., Procaine Pencillin G, Etc.) Patents (Class 514/199)
-
Patent number: 11744853Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.Type: GrantFiled: October 29, 2021Date of Patent: September 5, 2023Assignee: Dyve Biosciences, Inc.Inventor: Ryan Beal
-
Patent number: 10265404Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.Type: GrantFiled: November 13, 2013Date of Patent: April 23, 2019Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Irakliy Papiashvili
-
Patent number: 10265330Abstract: The present invention relates to a pharmaceutical composition and methods of treating and/or preventing mastitis in non-human mammals. More particularly, the present invention relates to the treatment of mastitis in cows. The pharmaceutical composition comprises a mixture of a phosphonic acid and at least one antimicrobial.Type: GrantFiled: June 25, 2013Date of Patent: April 23, 2019Assignee: BAYER ANIMAL HEALTH GMBHInventors: Robrecht Froyman, Heinz-Georg Wetzstein, Kristine Fraatz, Wolfgang Wiehl
-
Patent number: 8906861Abstract: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.Type: GrantFiled: January 28, 2009Date of Patent: December 9, 2014Assignee: Allergan, Inc.Inventors: Walter L. Tien, Richard S. Graham, James N. Chang
-
Patent number: 8889733Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: GrantFiled: January 14, 2013Date of Patent: November 18, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
-
Publication number: 20140200189Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: ApplicationFiled: January 14, 2013Publication date: July 17, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
-
Publication number: 20140186467Abstract: A composition comprising at least one penicillin, at least one iron source, and at least one oil, method of making, and method of use thereof are described. Although suitable for many forms and uses, the composition is, in some embodiments, suitable as a pharmaceutical composition, and, in some embodiments, as an antiviral composition capable of restoring T cell count and eradicating HIV virus from patients suffering from HIV/AIDS and other diseases including Tuberculosis.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Applicant: BNEERS CORP.Inventors: Comfort Wynee DIGGS, Christian SOMUAH, Isaac Dowor JOEMAH, II
-
Patent number: 8741876Abstract: A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or metronidazoles.Type: GrantFiled: February 24, 2010Date of Patent: June 3, 2014Assignees: Nobuhiro Sato, Wakamoto Pharmaceutical Co., LtdInventors: Nobuhiro Sato, Toshifumi Okusa, Isao Okayasu
-
Publication number: 20140147503Abstract: The present invention relates to a pharmaceutical composition comprising deferasirox, a process for preparing such pharmaceutical composition, and its use in the treatment of chronic iron overload. The pharmaceutical composition comprises nanosized deferasirox having improved surface area and solubility. It also relates to a method for treatment of chronic iron overload which comprises administering a pharmaceutical composition comprising nanosized deferasirox.Type: ApplicationFiled: September 30, 2011Publication date: May 29, 2014Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Publication number: 20140088069Abstract: An antibacterial composition is provided including a combination of a ?-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided.Type: ApplicationFiled: November 29, 2013Publication date: March 27, 2014Inventors: Eric D. Brown, Maya Farha, Alexander Leung, Gerry Wright, Kalinka Koteva, Ted Sewell, Linda Ejim
-
Publication number: 20140066365Abstract: A product comprising at least one given antibiotic and a calixarene for use as medicament.Type: ApplicationFiled: April 11, 2012Publication date: March 6, 2014Inventors: Marion Grare, Raphaƫl, Emmanuel Duval
-
Publication number: 20130116210Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: October 4, 2012Publication date: May 9, 2013Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: The Regents of the University of California, Otonomy, Inc.
-
Publication number: 20130053336Abstract: The invention relates to a method for treating infections of bacteria of the Chlamydiaceae family using a ?-lactam. The invention also relates to a method for treating diseases caused by an infection of bacteria of the Chlamydiaceae family using a ?-lactam.Type: ApplicationFiled: January 13, 2011Publication date: February 28, 2013Inventors: Philippe Verbeke, Maud Dumoux, Colette Kanellopoulos
-
Patent number: 8298543Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: GrantFiled: May 6, 2011Date of Patent: October 30, 2012Assignee: Trius Therapeutics, Inc.Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Patent number: 8299052Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.Type: GrantFiled: May 7, 2007Date of Patent: October 30, 2012Assignee: Shionogi Inc.Inventors: Henry H. Flanner, Robert Guttendorf, Donald Treacy, Susan P. Clausen, Beth A. Burnside
-
Patent number: 8236334Abstract: Disclosed is a method for protecting a tree from insects by injecting the tree with a fungicide and/or an antibiotic, and applying a composition to the surface of the tree, said composition comprising water, an insect repellent, an antihistamine, and an insect poison.Type: GrantFiled: September 6, 2005Date of Patent: August 7, 2012Inventor: James S. Bass
-
Publication number: 20120157371Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: December 12, 2011Publication date: June 21, 2012Inventors: Chongxi YU, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
-
Publication number: 20120114696Abstract: This disclosure relates to materials and methods for inhibiting Botulinum neurotoxin, and more particularly to materials and methods for inhibiting the zinc endopeptidase of Botulinum neurotoxin serotypes A, D and/or E (BoNTA, BoNTD and/or BoNTE).Type: ApplicationFiled: July 29, 2010Publication date: May 10, 2012Inventors: Yuan-Ping Pang, Jewn Giew Park, Shaohua Wang, Anuradha Vummenthala, Rajesh K. Mishra, Jon Davis, Charles B. Millard, James J. Schmidt
-
Publication number: 20120065182Abstract: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).Type: ApplicationFiled: November 18, 2011Publication date: March 15, 2012Applicant: Taro Pharmaceuticals North America, Inc.Inventors: Shen GAO, Daniel A. Moros, Satish Asotra
-
Publication number: 20110294774Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: ApplicationFiled: May 6, 2011Publication date: December 1, 2011Applicant: TRIUS THERAPEUTICSInventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Publication number: 20110269723Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: July 12, 2011Publication date: November 3, 2011Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli Wang, Zoltan Bodor
-
Patent number: 8021665Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: GrantFiled: December 8, 2006Date of Patent: September 20, 2011Assignee: Trius Therapeutics, Inc.Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Publication number: 20110182891Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.Type: ApplicationFiled: June 30, 2009Publication date: July 28, 2011Applicant: Abbott GmbH & Co., KGInventors: Bernd Liepold, Jƶrg Breitenbach, Markus MƤgerlein, Claudia PackhƤuser, Thomas K. Kessler
-
Patent number: 7807623Abstract: This invention pertains to the discovery administration of a CCK receptor agonist can increase urinary sodium excretion and/or free water excretion in a mammal. CCK receptor agonist can thereby be used in the treatment of conditions such high blood pressure, fluid retention associated with heart failure, fluid retention associated with acute or chronic kidney failure, fluid retention associated with cirrhosis, fluid retention associated with liver failure, calcium kidney stones, nephrogenic diabetes insipidus, and renal tubular acidosis.Type: GrantFiled: December 8, 2006Date of Patent: October 5, 2010Assignee: The Regents of the University of CaliforniaInventors: Joseph R. Pisegna, Stephen Wank
-
Patent number: 7807151Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.Type: GrantFiled: April 23, 2008Date of Patent: October 5, 2010Assignee: Ganeden Biotech, IncorporatedInventor: Sean Farmer
-
Patent number: 7759334Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.Type: GrantFiled: June 27, 2007Date of Patent: July 20, 2010Assignee: Pharmaceutical Solutions, Inc.Inventors: Michael A. Strobel, Pat Soderlund, Jr.
-
Patent number: 7723389Abstract: The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent.Type: GrantFiled: November 4, 2002Date of Patent: May 25, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Leonard A. Herzenberg, Leonore A. Herzenberg, Stephen C. De Rosa, James Andrus
-
Patent number: 7365047Abstract: This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.Type: GrantFiled: September 27, 2000Date of Patent: April 29, 2008Assignee: The Regents of the University of CaliforniaInventor: Joseph R. Pisegna
-
Patent number: 7244720Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.Type: GrantFiled: August 12, 2002Date of Patent: July 17, 2007Assignee: Pharmaceutical Solutions, Inc.Inventors: Michael Strobel, Pat Soderland
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 6946477Abstract: One aspect of the present invention relates to novel heterocyclic compounds comprising urea functionality. A second aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as ligands for various cellular receptors, including opioid receptors, other G-protein-coupled receptors and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as analgesics.Type: GrantFiled: November 5, 2002Date of Patent: September 20, 2005Assignee: Sepracor Inc.Inventors: Brian M. Aquila, Gregory D. Cuny, James R. Hauske, Liming Shao, Xinhe Wu
-
Patent number: 6833389Abstract: Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful for the treatment Chlamydia pneumoniae infections is described.Type: GrantFiled: December 11, 2001Date of Patent: December 21, 2004Assignee: Zambon Group S.p.A.Inventors: Giovanni Battista Colombo, Domenico Ungheri, Luciano Licciardello, Maria Rita Gismondo, Lorenzo Drago
-
Patent number: 6756369Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: GrantFiled: March 19, 2002Date of Patent: June 29, 2004Assignee: Vanderbilt UniversityInventors: William M. Mitchell, Charles W. Stratton
-
Patent number: 6743440Abstract: A composition, preferably used to reduce methane formation in a ruminant, wherein the composition is a combination of a polycyclic quinone compound and an ionophore compound.Type: GrantFiled: October 10, 2000Date of Patent: June 1, 2004Assignee: Arkion Life Sciences LLCInventor: Kenneth E. Ballinger, Jr.
-
Patent number: 6664239Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: GrantFiled: March 19, 2002Date of Patent: December 16, 2003Assignee: Vanderbilt UniversityInventors: William M. Mitchell, Charles W. Stratton
-
Patent number: 6627625Abstract: Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.Type: GrantFiled: August 16, 2000Date of Patent: September 30, 2003Assignee: Revaax Pharmaceuticals, LLCInventor: Gary A. Koppel
-
Patent number: 6599892Abstract: Derivatives of 7-alkylidene cephalosporanic acid sulfone and the pharmaceutically active salts thereof are found to be potent inhibitors of &bgr;-lactamase enzymes.Type: GrantFiled: July 30, 2001Date of Patent: July 29, 2003Assignee: Research Corporation Technologies, Inc.Inventors: John D. Buynak, Brian Bachmann
-
Patent number: 6537985Abstract: An antibiotic formulation in a true solution is provided. This formulation includes an antibiotic and N-methyl-2-pyrrolidone. It also may include a preservative, an antioxidant, and/or an additive. The antibiotic is a beta lactam, such as a penicillin, a cephalosporin, other beta lactams, or combinations thereof. The formulation is made by dissolving the antibiotic in the N-methyl-2-pyrrolidone. The antibiotic formulation is suitable for use at temperatures below about 0° C. and without agitation. Further, the antibiotic formulation in true solution can be made with non-sterile ingredients and can be filtered to remove impurities.Type: GrantFiled: November 30, 2001Date of Patent: March 25, 2003Assignee: Phoenix Scientific, Inc.Inventors: Richard Mihalik, John R. Carpenter, Heidi M. P. Faris
-
Patent number: 6492354Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.Type: GrantFiled: December 8, 2000Date of Patent: December 10, 2002Assignee: Pharmaceutical Solutions, Inc.Inventors: Michael Strobel, Pat Soderlund
-
Patent number: 6461607Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.Type: GrantFiled: August 5, 1999Date of Patent: October 8, 2002Assignee: Ganeden Biotech, Inc.Inventor: Sean Farmer
-
Patent number: 6429191Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.Type: GrantFiled: March 30, 2001Date of Patent: August 6, 2002Assignee: Genentech, Inc.Inventor: Wei-Qiang Gao
-
Patent number: 6417174Abstract: The invention provides novel non-&bgr;-lactam inhibitors of &bgr;-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with &bgr;-lactam antibiotics to treat 62 -lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial by themselves. Finally, the invention provides a pharmaceutical composition comprising these compounds.Type: GrantFiled: June 6, 2000Date of Patent: July 9, 2002Assignee: Northwestern UniversityInventors: Brian Shoichet, Scott Weston
-
Patent number: 6316015Abstract: A surface is provided with antibiotic or antiseptic properties. A solid substrate is modified by covalently fixing one or more spacers having reactive extremities via a proximate reactive extremity, and one or more antibiotic, bactericidal, viricidal or fungicidal molecules covalently bonded to a distal reactive extremity of the spacer or spacers. The spacer has formula A1—(CH2)n—A2, where: A1 is where Z=H, OH or Cl; or SiY3 where Y3 is Cl or an alkoxy group containing 1 to 3 carbon atoms; n is in the range 2 to 18; A2 is selected from the following residues: CH═CH2, OH, halogen or where Z=H, OH or Cl.Type: GrantFiled: February 1, 1999Date of Patent: November 13, 2001Assignees: Institut Curie, Centre National de la Recherche ScientifiqueInventors: Francis Rondelez, Pascal Bezou, Othman Bouloussa
-
Patent number: 6303644Abstract: The invention relates to the use of proton pump inhibitors as combination therapeutics in the treatment of bacterial diseases which do not affect the gastrointestinal track using antibacterially active compounds.Type: GrantFiled: January 27, 2000Date of Patent: October 16, 2001Assignee: Byk Gulden Lomberg Chemische Fabrik GmbHInventor: Klaus Tuch
-
Patent number: 6225304Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.Type: GrantFiled: February 17, 1999Date of Patent: May 1, 2001Assignee: Pharmaceutical Solutions, Inc.Inventors: Michael Strobel, Pat Soderland
-
Patent number: 6225282Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.Type: GrantFiled: January 2, 1997Date of Patent: May 1, 2001Assignee: Genentech, Inc.Inventor: Wei-Qiang Gao
-
Patent number: 6221859Abstract: The present invention relates to novel 2-(naphthosultamyl)methyl-carbapenem antibacterial agents or pharmaceutically acceptable salts thereof in combination with other &bgr;-lactams, which are useful in treating and preventing enterococcal infections. The combinations have anti-PBP5 activity as well as activity against the critical PBPs of sensitive isolates. The antibacterial compositions of the present invention thus comprise an important contribution to therapy for treating infections caused by these difficult to control pathogens. This combination is also useful against gram positive microorganisms, especially methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).Type: GrantFiled: August 27, 1999Date of Patent: April 24, 2001Assignee: Merck & Co., Inc.Inventors: Karen L. Dorso, Jesse J. Jackson, Charles J. Gill, Joyce Kohler, Lynn L. Silver
-
Patent number: 6187768Abstract: A kit and for flushing a medical device a method of preparing the kit is disclosed. The kit includes a container containing a mixed solution a unit dose of a pharmacologically effective amount of an antimicrobial agent and a second agent. The mixed solution has been mixed in a carrier solution and lyophilized. The second agent is an anticoagulant, an antithrombotic agent or a chelating agent. The kit and method are useful for maintaining the patency of indwelling medical devices such as catheters and for preventing infections caused by bacterial growth in catheters.Type: GrantFiled: June 1, 1999Date of Patent: February 13, 2001Assignee: Becton, Dickinson and CompanyInventors: Charles J. Welle, Steven C. Felton, Mohammad A. Khan
-
Patent number: 6159706Abstract: The present invention provides a method for targeting toxic antimetabolites to gram negative infections. It provides a means of taking advantage of a key disease resistance mechanism to activate these drugs locally, and to overcome the resistance phenotype of the microbes. The invention further provides a method for selecting for antibiotic sensitivity, since a likely mechanism by which organisms are likely to gain resistance to the prodrugs is via loss of enzyme activity, which will make the bacteria sensitive to antibiotics once again.Type: GrantFiled: December 18, 1998Date of Patent: December 12, 2000Assignee: NewBiotics, Inc.Inventor: H. Michael Shepard
-
Patent number: 6143742Abstract: The treatment of for arresting the destructive effects of proteolytic enzymes produced by a host infecting organism, such as "flesh eating bacteria", is carried out using therapy with includes the administration of one or more protease inhibitors.Type: GrantFiled: December 11, 1998Date of Patent: November 7, 2000Assignee: Fuisz Technologies LtdInventor: Richard C. Fuisz